human syn proteins Search Results


ubiquitin vinyl sulfone  (Boston Biochem)
93
Boston Biochem ubiquitin vinyl sulfone
(A) Flowchart followed for UbL signature characterization. Extracts from parental and chemoresistant HL-60 or U937 cells were first supplemented with recombinant UbLs (to avoid rate-limiting amounts of the modifiers) and UbL-vinyl-sulfones (to inhibit UbL deconjugating activities). They were then incubated with protein ProtoArrays. After extensive washes, the arrays were incubated with, first, a primary mouse anti–SUMO-1 antibody and a rabbit anti-Flag antiserum recognizing the Flag-tag present on the recombinant <t>ubiquitin</t> added to the reaction and, then, appropriate fluorescent secondary antibodies. Fluorescence signals were processed using the PAA R package. The statistical analysis was performed to identify a UbL signature of chemoresistance, as described in the Materials and Methods section. Three independent experiments were performed for each cell line. (B) IC 50 of chemosensitive and chemoresistant acute myeloid leukemia cell lines. IC 50 of chemosensitive parental HL-60 and U937 (wt) cells and of their resistant counterparts (see the Materials and Methods section) (ARA-R and DNR-R) was assayed after 24 h of exposure to drugs. n = 3, Mean ± SEM, paired t test with * corresponding to P < 0.05. (C) Identification of ubiquitylated- and SUMOylated proteins. Normalized Ub and SUMO-1 fluorescence data obtained on all arrays incubated with extracts were compared with averaged signals on control arrays (extracts supplemented with NEM to inhibit UbL conjugation activities) to identify robustly UbL-conjugated proteins. Proteins showing significant differences between the two groups when using both the Welch- and the Wilcoxon–Mann–Whitney statistical tests and having mean fluorescence intensity values higher than 800 (arbitrary threshold) on ProtoArrays were selected for further analysis. The Venn diagram shows the number or proteins identified as modified by SUMO-1 and/or ubiquitin.
Ubiquitin Vinyl Sulfone, supplied by Boston Biochem, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ubiquitin vinyl sulfone/product/Boston Biochem
Average 93 stars, based on 1 article reviews
ubiquitin vinyl sulfone - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
synthetic peptide  (Aviva Systems)
92
Aviva Systems synthetic peptide
(A) Flowchart followed for UbL signature characterization. Extracts from parental and chemoresistant HL-60 or U937 cells were first supplemented with recombinant UbLs (to avoid rate-limiting amounts of the modifiers) and UbL-vinyl-sulfones (to inhibit UbL deconjugating activities). They were then incubated with protein ProtoArrays. After extensive washes, the arrays were incubated with, first, a primary mouse anti–SUMO-1 antibody and a rabbit anti-Flag antiserum recognizing the Flag-tag present on the recombinant <t>ubiquitin</t> added to the reaction and, then, appropriate fluorescent secondary antibodies. Fluorescence signals were processed using the PAA R package. The statistical analysis was performed to identify a UbL signature of chemoresistance, as described in the Materials and Methods section. Three independent experiments were performed for each cell line. (B) IC 50 of chemosensitive and chemoresistant acute myeloid leukemia cell lines. IC 50 of chemosensitive parental HL-60 and U937 (wt) cells and of their resistant counterparts (see the Materials and Methods section) (ARA-R and DNR-R) was assayed after 24 h of exposure to drugs. n = 3, Mean ± SEM, paired t test with * corresponding to P < 0.05. (C) Identification of ubiquitylated- and SUMOylated proteins. Normalized Ub and SUMO-1 fluorescence data obtained on all arrays incubated with extracts were compared with averaged signals on control arrays (extracts supplemented with NEM to inhibit UbL conjugation activities) to identify robustly UbL-conjugated proteins. Proteins showing significant differences between the two groups when using both the Welch- and the Wilcoxon–Mann–Whitney statistical tests and having mean fluorescence intensity values higher than 800 (arbitrary threshold) on ProtoArrays were selected for further analysis. The Venn diagram shows the number or proteins identified as modified by SUMO-1 and/or ubiquitin.
Synthetic Peptide, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/synthetic peptide/product/Aviva Systems
Average 92 stars, based on 1 article reviews
synthetic peptide - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
adeno-associated virus (aav) targeting to knockdown the entpd1 gene by shrna-entpd1 via cre-loxp strategy  (BrainVTA (Wuhan) Co Ltd)
90
BrainVTA (Wuhan) Co Ltd adeno-associated virus (aav) targeting to knockdown the entpd1 gene by shrna-entpd1 via cre-loxp strategy
(A) Flowchart followed for UbL signature characterization. Extracts from parental and chemoresistant HL-60 or U937 cells were first supplemented with recombinant UbLs (to avoid rate-limiting amounts of the modifiers) and UbL-vinyl-sulfones (to inhibit UbL deconjugating activities). They were then incubated with protein ProtoArrays. After extensive washes, the arrays were incubated with, first, a primary mouse anti–SUMO-1 antibody and a rabbit anti-Flag antiserum recognizing the Flag-tag present on the recombinant <t>ubiquitin</t> added to the reaction and, then, appropriate fluorescent secondary antibodies. Fluorescence signals were processed using the PAA R package. The statistical analysis was performed to identify a UbL signature of chemoresistance, as described in the Materials and Methods section. Three independent experiments were performed for each cell line. (B) IC 50 of chemosensitive and chemoresistant acute myeloid leukemia cell lines. IC 50 of chemosensitive parental HL-60 and U937 (wt) cells and of their resistant counterparts (see the Materials and Methods section) (ARA-R and DNR-R) was assayed after 24 h of exposure to drugs. n = 3, Mean ± SEM, paired t test with * corresponding to P < 0.05. (C) Identification of ubiquitylated- and SUMOylated proteins. Normalized Ub and SUMO-1 fluorescence data obtained on all arrays incubated with extracts were compared with averaged signals on control arrays (extracts supplemented with NEM to inhibit UbL conjugation activities) to identify robustly UbL-conjugated proteins. Proteins showing significant differences between the two groups when using both the Welch- and the Wilcoxon–Mann–Whitney statistical tests and having mean fluorescence intensity values higher than 800 (arbitrary threshold) on ProtoArrays were selected for further analysis. The Venn diagram shows the number or proteins identified as modified by SUMO-1 and/or ubiquitin.
Adeno Associated Virus (Aav) Targeting To Knockdown The Entpd1 Gene By Shrna Entpd1 Via Cre Loxp Strategy, supplied by BrainVTA (Wuhan) Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adeno-associated virus (aav) targeting to knockdown the entpd1 gene by shrna-entpd1 via cre-loxp strategy/product/BrainVTA (Wuhan) Co Ltd
Average 90 stars, based on 1 article reviews
adeno-associated virus (aav) targeting to knockdown the entpd1 gene by shrna-entpd1 via cre-loxp strategy - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
α-syn  (Human Protein Atlas)
90
Human Protein Atlas α-syn
(A) Flowchart followed for UbL signature characterization. Extracts from parental and chemoresistant HL-60 or U937 cells were first supplemented with recombinant UbLs (to avoid rate-limiting amounts of the modifiers) and UbL-vinyl-sulfones (to inhibit UbL deconjugating activities). They were then incubated with protein ProtoArrays. After extensive washes, the arrays were incubated with, first, a primary mouse anti–SUMO-1 antibody and a rabbit anti-Flag antiserum recognizing the Flag-tag present on the recombinant <t>ubiquitin</t> added to the reaction and, then, appropriate fluorescent secondary antibodies. Fluorescence signals were processed using the PAA R package. The statistical analysis was performed to identify a UbL signature of chemoresistance, as described in the Materials and Methods section. Three independent experiments were performed for each cell line. (B) IC 50 of chemosensitive and chemoresistant acute myeloid leukemia cell lines. IC 50 of chemosensitive parental HL-60 and U937 (wt) cells and of their resistant counterparts (see the Materials and Methods section) (ARA-R and DNR-R) was assayed after 24 h of exposure to drugs. n = 3, Mean ± SEM, paired t test with * corresponding to P < 0.05. (C) Identification of ubiquitylated- and SUMOylated proteins. Normalized Ub and SUMO-1 fluorescence data obtained on all arrays incubated with extracts were compared with averaged signals on control arrays (extracts supplemented with NEM to inhibit UbL conjugation activities) to identify robustly UbL-conjugated proteins. Proteins showing significant differences between the two groups when using both the Welch- and the Wilcoxon–Mann–Whitney statistical tests and having mean fluorescence intensity values higher than 800 (arbitrary threshold) on ProtoArrays were selected for further analysis. The Venn diagram shows the number or proteins identified as modified by SUMO-1 and/or ubiquitin.
α Syn, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/α-syn/product/Human Protein Atlas
Average 90 stars, based on 1 article reviews
α-syn - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
human α-syn protein  (Brookhaven Instruments)
90
Brookhaven Instruments human α-syn protein
(A) Flowchart followed for UbL signature characterization. Extracts from parental and chemoresistant HL-60 or U937 cells were first supplemented with recombinant UbLs (to avoid rate-limiting amounts of the modifiers) and UbL-vinyl-sulfones (to inhibit UbL deconjugating activities). They were then incubated with protein ProtoArrays. After extensive washes, the arrays were incubated with, first, a primary mouse anti–SUMO-1 antibody and a rabbit anti-Flag antiserum recognizing the Flag-tag present on the recombinant <t>ubiquitin</t> added to the reaction and, then, appropriate fluorescent secondary antibodies. Fluorescence signals were processed using the PAA R package. The statistical analysis was performed to identify a UbL signature of chemoresistance, as described in the Materials and Methods section. Three independent experiments were performed for each cell line. (B) IC 50 of chemosensitive and chemoresistant acute myeloid leukemia cell lines. IC 50 of chemosensitive parental HL-60 and U937 (wt) cells and of their resistant counterparts (see the Materials and Methods section) (ARA-R and DNR-R) was assayed after 24 h of exposure to drugs. n = 3, Mean ± SEM, paired t test with * corresponding to P < 0.05. (C) Identification of ubiquitylated- and SUMOylated proteins. Normalized Ub and SUMO-1 fluorescence data obtained on all arrays incubated with extracts were compared with averaged signals on control arrays (extracts supplemented with NEM to inhibit UbL conjugation activities) to identify robustly UbL-conjugated proteins. Proteins showing significant differences between the two groups when using both the Welch- and the Wilcoxon–Mann–Whitney statistical tests and having mean fluorescence intensity values higher than 800 (arbitrary threshold) on ProtoArrays were selected for further analysis. The Venn diagram shows the number or proteins identified as modified by SUMO-1 and/or ubiquitin.
Human α Syn Protein, supplied by Brookhaven Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human α-syn protein/product/Brookhaven Instruments
Average 90 stars, based on 1 article reviews
human α-syn protein - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
recombinant human tyrosine-protein kinasefyn/syn  (RayBiotech)
N/A
Recombinant human tyrosine-protein kinaseFyn/Syn protein derived from E.coli
  Buy from Supplier

Image Search Results


(A) Flowchart followed for UbL signature characterization. Extracts from parental and chemoresistant HL-60 or U937 cells were first supplemented with recombinant UbLs (to avoid rate-limiting amounts of the modifiers) and UbL-vinyl-sulfones (to inhibit UbL deconjugating activities). They were then incubated with protein ProtoArrays. After extensive washes, the arrays were incubated with, first, a primary mouse anti–SUMO-1 antibody and a rabbit anti-Flag antiserum recognizing the Flag-tag present on the recombinant ubiquitin added to the reaction and, then, appropriate fluorescent secondary antibodies. Fluorescence signals were processed using the PAA R package. The statistical analysis was performed to identify a UbL signature of chemoresistance, as described in the Materials and Methods section. Three independent experiments were performed for each cell line. (B) IC 50 of chemosensitive and chemoresistant acute myeloid leukemia cell lines. IC 50 of chemosensitive parental HL-60 and U937 (wt) cells and of their resistant counterparts (see the Materials and Methods section) (ARA-R and DNR-R) was assayed after 24 h of exposure to drugs. n = 3, Mean ± SEM, paired t test with * corresponding to P < 0.05. (C) Identification of ubiquitylated- and SUMOylated proteins. Normalized Ub and SUMO-1 fluorescence data obtained on all arrays incubated with extracts were compared with averaged signals on control arrays (extracts supplemented with NEM to inhibit UbL conjugation activities) to identify robustly UbL-conjugated proteins. Proteins showing significant differences between the two groups when using both the Welch- and the Wilcoxon–Mann–Whitney statistical tests and having mean fluorescence intensity values higher than 800 (arbitrary threshold) on ProtoArrays were selected for further analysis. The Venn diagram shows the number or proteins identified as modified by SUMO-1 and/or ubiquitin.

Journal: Life Science Alliance

Article Title: Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies

doi: 10.26508/lsa.201900577

Figure Lengend Snippet: (A) Flowchart followed for UbL signature characterization. Extracts from parental and chemoresistant HL-60 or U937 cells were first supplemented with recombinant UbLs (to avoid rate-limiting amounts of the modifiers) and UbL-vinyl-sulfones (to inhibit UbL deconjugating activities). They were then incubated with protein ProtoArrays. After extensive washes, the arrays were incubated with, first, a primary mouse anti–SUMO-1 antibody and a rabbit anti-Flag antiserum recognizing the Flag-tag present on the recombinant ubiquitin added to the reaction and, then, appropriate fluorescent secondary antibodies. Fluorescence signals were processed using the PAA R package. The statistical analysis was performed to identify a UbL signature of chemoresistance, as described in the Materials and Methods section. Three independent experiments were performed for each cell line. (B) IC 50 of chemosensitive and chemoresistant acute myeloid leukemia cell lines. IC 50 of chemosensitive parental HL-60 and U937 (wt) cells and of their resistant counterparts (see the Materials and Methods section) (ARA-R and DNR-R) was assayed after 24 h of exposure to drugs. n = 3, Mean ± SEM, paired t test with * corresponding to P < 0.05. (C) Identification of ubiquitylated- and SUMOylated proteins. Normalized Ub and SUMO-1 fluorescence data obtained on all arrays incubated with extracts were compared with averaged signals on control arrays (extracts supplemented with NEM to inhibit UbL conjugation activities) to identify robustly UbL-conjugated proteins. Proteins showing significant differences between the two groups when using both the Welch- and the Wilcoxon–Mann–Whitney statistical tests and having mean fluorescence intensity values higher than 800 (arbitrary threshold) on ProtoArrays were selected for further analysis. The Venn diagram shows the number or proteins identified as modified by SUMO-1 and/or ubiquitin.

Article Snippet: Human protein arrays (ProtoArrays V5.0; Life Technologies) kept at −20°C were equilibrated at 4°C for 15 min and, then, saturated with the ProtoArray Blocking Buffer (PA055; Life Technologies) supplemented with Synthetic Block (PA017; Life Technologies) and 1 mM DTT at 4°C for 1 h. To probe ProtoArrays for UbL protein modification, cell extracts were first supplemented with 5 μM ubiquitin-vinyl sulfone, 2.5 μM SUMO1-vinyl sulfone, and 2.5 µM SUMO2-vinyl sulfone (Boston Biochem) to inhibit the corresponding UbL-deconjugating enzymes.

Techniques: Recombinant, Incubation, FLAG-tag, Fluorescence, Conjugation Assay, MANN-WHITNEY, Modification

(A) Identification of UbL-modified biomarkers of acute myeloid leukemias chemoresistance. Modification levels of the proteins modified by ubiquitin (left panel) or SUMO-1 (central panel) selected in were compared between all parental (U937 and HL-60) and drug-resistant (ARA-R or DNR-R) sublines. Differentially modified proteins with significant P -values in both Wilcoxon signed rank- and one sample t test and with a drug-resistant versus parental cell ratio higher than 1.25 or lower than 0.8 are indicated in red for ubiquitylated proteins and in blue for SUMOylated ones. The Venn diagram shows the overlap between differentially ubiquitylated- and SUMOylated proteins. (B) Identification of UbL-conjugated biomarkers specific for HL-60 and U937 cell resistance to Ara-C or DNR. Statistical analyses between drug-resistant and parental cells were performed separately for U937 and HL-60 cell lines and for each drug resistance. The number of proteins showing a significant P -value in one sample t test and a ratio between drug-resistant and parental cells higher than 1.5, or lower than 0.66, are shown. (C) Ontology analysis of the UbL signature. An ontology analysis of the 122 proteins of the UbL signature was performed using the Panther software.

Journal: Life Science Alliance

Article Title: Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies

doi: 10.26508/lsa.201900577

Figure Lengend Snippet: (A) Identification of UbL-modified biomarkers of acute myeloid leukemias chemoresistance. Modification levels of the proteins modified by ubiquitin (left panel) or SUMO-1 (central panel) selected in were compared between all parental (U937 and HL-60) and drug-resistant (ARA-R or DNR-R) sublines. Differentially modified proteins with significant P -values in both Wilcoxon signed rank- and one sample t test and with a drug-resistant versus parental cell ratio higher than 1.25 or lower than 0.8 are indicated in red for ubiquitylated proteins and in blue for SUMOylated ones. The Venn diagram shows the overlap between differentially ubiquitylated- and SUMOylated proteins. (B) Identification of UbL-conjugated biomarkers specific for HL-60 and U937 cell resistance to Ara-C or DNR. Statistical analyses between drug-resistant and parental cells were performed separately for U937 and HL-60 cell lines and for each drug resistance. The number of proteins showing a significant P -value in one sample t test and a ratio between drug-resistant and parental cells higher than 1.5, or lower than 0.66, are shown. (C) Ontology analysis of the UbL signature. An ontology analysis of the 122 proteins of the UbL signature was performed using the Panther software.

Article Snippet: Human protein arrays (ProtoArrays V5.0; Life Technologies) kept at −20°C were equilibrated at 4°C for 15 min and, then, saturated with the ProtoArray Blocking Buffer (PA055; Life Technologies) supplemented with Synthetic Block (PA017; Life Technologies) and 1 mM DTT at 4°C for 1 h. To probe ProtoArrays for UbL protein modification, cell extracts were first supplemented with 5 μM ubiquitin-vinyl sulfone, 2.5 μM SUMO1-vinyl sulfone, and 2.5 µM SUMO2-vinyl sulfone (Boston Biochem) to inhibit the corresponding UbL-deconjugating enzymes.

Techniques: Modification, Software

Modification levels of the proteins modified by ubiquitin selected in were compared between all parental (U937 and HL-60) and drug-resistant (ARA-R or DNR-R) sublines. Differentially modified proteins with a drug-resistant versus parental cell ratio higher than 1.25 or lower than 0.8 are named.

Journal: Life Science Alliance

Article Title: Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies

doi: 10.26508/lsa.201900577

Figure Lengend Snippet: Modification levels of the proteins modified by ubiquitin selected in were compared between all parental (U937 and HL-60) and drug-resistant (ARA-R or DNR-R) sublines. Differentially modified proteins with a drug-resistant versus parental cell ratio higher than 1.25 or lower than 0.8 are named.

Article Snippet: Human protein arrays (ProtoArrays V5.0; Life Technologies) kept at −20°C were equilibrated at 4°C for 15 min and, then, saturated with the ProtoArray Blocking Buffer (PA055; Life Technologies) supplemented with Synthetic Block (PA017; Life Technologies) and 1 mM DTT at 4°C for 1 h. To probe ProtoArrays for UbL protein modification, cell extracts were first supplemented with 5 μM ubiquitin-vinyl sulfone, 2.5 μM SUMO1-vinyl sulfone, and 2.5 µM SUMO2-vinyl sulfone (Boston Biochem) to inhibit the corresponding UbL-deconjugating enzymes.

Techniques: Modification

(A) Selection of the best predictive proteins. A list of 30 predictors among the 122 signature proteins was chosen to run a genetic algorithm. These predictors corresponded to 23 proteins modified either by ubiquitin (Ub), SUMO (Su), or both UbLs. The rate of selection of each of these proteins and its associated UbL (Ub or Su) is indicated on the graph. The proteins were separated in five subsets for linear discriminant analysis analysis. (B, C) Probability of acute myeloid leukemias sensitivity/resistance using the subset 2 solution. (B, C) The seven proteins showing the highest rate of selection in the genetic algorithm (subset 2) were used for linear discriminant analysis to predict the probability of resistance for the U937 and HL60 cell lines (B) or patient samples (C). Cells were considered sensitive to chemotherapy if the probability to belong to the group of resistant cells was below 50% and resistant if over 50%.

Journal: Life Science Alliance

Article Title: Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies

doi: 10.26508/lsa.201900577

Figure Lengend Snippet: (A) Selection of the best predictive proteins. A list of 30 predictors among the 122 signature proteins was chosen to run a genetic algorithm. These predictors corresponded to 23 proteins modified either by ubiquitin (Ub), SUMO (Su), or both UbLs. The rate of selection of each of these proteins and its associated UbL (Ub or Su) is indicated on the graph. The proteins were separated in five subsets for linear discriminant analysis analysis. (B, C) Probability of acute myeloid leukemias sensitivity/resistance using the subset 2 solution. (B, C) The seven proteins showing the highest rate of selection in the genetic algorithm (subset 2) were used for linear discriminant analysis to predict the probability of resistance for the U937 and HL60 cell lines (B) or patient samples (C). Cells were considered sensitive to chemotherapy if the probability to belong to the group of resistant cells was below 50% and resistant if over 50%.

Article Snippet: Human protein arrays (ProtoArrays V5.0; Life Technologies) kept at −20°C were equilibrated at 4°C for 15 min and, then, saturated with the ProtoArray Blocking Buffer (PA055; Life Technologies) supplemented with Synthetic Block (PA017; Life Technologies) and 1 mM DTT at 4°C for 1 h. To probe ProtoArrays for UbL protein modification, cell extracts were first supplemented with 5 μM ubiquitin-vinyl sulfone, 2.5 μM SUMO1-vinyl sulfone, and 2.5 µM SUMO2-vinyl sulfone (Boston Biochem) to inhibit the corresponding UbL-deconjugating enzymes.

Techniques: Selection, Modification